Related Experiment Video
Updated: Dec 14, 2025

Ultrasound Cyclo Plasty in Eyes with Glaucoma
Published on: January 26, 2018
Perioperative Propranolol: A Useful Adjunct for Glaucoma Surgery in Sturge-Weber Syndrome
Sushmita Kaushik1, Pankaj Kataria1, Gunjan Joshi1
1Advanced Eye Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Insights
Perioperative oral propranolol significantly reduced sight-threatening choroidal effusions in Sturge-Weber syndrome (SWS) patients undergoing glaucoma surgery. This treatment appears safe and effective for managing ocular complications in SWS.
Area of Science:
- Ophthalmology
- Vascular Disorders
- Pharmacology
Background:
- Sturge-Weber syndrome (SWS) presents ocular issues like choroidal hemangioma and glaucoma.
- Glaucoma surgery in SWS patients risks sight-threatening choroidal effusions.
- The efficacy of propranolol for choroidal hemangioma is understudied.
Purpose of the Study:
- To investigate the role of perioperative oral propranolol in preventing choroidal effusions during glaucoma surgery in SWS patients.
- To assess the safety and efficacy of propranolol in this context.
Main Methods:
- A prospective, nonrandomized case series of 14 eyes from 12 SWS patients undergoing glaucoma surgery.
- Patients received oral propranolol (2 mg/kg/day) preoperatively and postoperatively.
- Outcomes were compared to historical controls (15 eyes from 14 patients) who did not receive propranolol.
Main Results:
- No patients in the propranolol group developed sight-threatening choroidal effusions.
- Two patients with bilateral SWS had peripheral effusions that resolved with medical management.
- The control group experienced a higher incidence of choroidal effusions, some requiring surgical intervention.
- No adverse effects of propranolol were observed.
Conclusions:
- Perioperative oral propranolol appears effective in minimizing sight-threatening choroidal effusions after glaucoma surgery in SWS patients.
- Propranolol demonstrates a favorable safety profile in this patient population.
- This approach may improve surgical outcomes for SWS patients with glaucoma.
Purpose:
Ocular manifestations of Sturge-Weber syndrome (SWS) include choroidal hemangioma and glaucoma. Intraocular pressure (IOP) reduction in these patients commonly is associated with sight-threatening choroidal effusions. Oral propranolol is the standard of care for infantile cutaneous hemangioma, but its role in choroidal hemangioma largely is unexplored. We studied the role of perioperative oral propranolol during glaucoma surgery in SWS.
Design:
Prospective, nonrandomized case series with historical controls.
Participants:
Fourteen eyes of 12 patients with SWS scheduled for glaucoma surgery were included, and the outcomes were compared with those of historical controls without propranolol use (15 eyes of 14 patients).
Methods:
Patients in the prospective cohort received oral propranolol 2 mg/kg of body weight daily in 2 divided doses 1 week before surgery and continued for 6 weeks after surgery. There was no modification (e.g., posterior sclerotomy) in the existing surgical technique. The historical control group was identified from records and SWS diagnosis validated by chart review.
Main Outcome Measures:
The incidence and extent of postoperative choroidal effusion, additional procedures required compared with the control group, and adverse effects of the drug in the prospective cohort.
Results:
Average follow-up was 25.7±12.1 months (95% confidence interval, 19.3-32.1 months). The intraocular pressure reduced from 25.2±9.7 mmHg at presentation to 16.25±6.2 mmHg, 14.6±4.5 mmHg, 13.7±6.4 mmHg, and 16.5±8.0 mmHg at 1 week, 1 month, 3 months, and 1 year after surgery, respectively. In the perioperative propranolol group, no patient demonstrated sight-threatening choroidal effusion within the vascular arcades. In the 2 patients with bilateral disease, both eyes of each patient showed peripheral choroidal effusion, which settled with medical treatment. Surgery was a repeat procedure in 3 of the 4 eyes. There were no adverse effects of propranolol in any patient. In the control group, 5 of 12 eyes showed peripheral choroidal effusion after primary glaucoma surgery, whereas 5 of 6 eyes that underwent repeat surgery failed demonstrated sight-threatening choroidal effusion requiring surgical intervention.
Conclusions:
Oral propranolol seems to be an effective method to minimize the development of sight-threatening choroidal effusion after glaucoma surgery in SWS.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Cardiomyopathy VII: Pre and Post Operative Nursing Management

